Connect
MJA
MJA

“SunSmart Plus”: the more informed use of sunscreens

Stephen R D Taylor
Med J Aust 2004; 180 (1): 36-37. || doi: 10.5694/j.1326-5377.2004.tb05773.x
Published online: 5 January 2004

Abstract

  • The sun protection factor (SPF) of sunscreens is determined by a testing protocol that specifies a sunscreen application rate of 2 mg/cm2 on the skin.

  • Most people, for cosmetic and economic reasons, only apply enough sunscreen to achieve an SPF of about a third or even a quarter of the level stated on the product.

  • To increase public awareness of the problem, manufacturers could be required to state both a “tested SPF” and an “expected SPF” (a third of the tested SPF) on product labelling.

  • The “SunSmart” message could be modified to make the public more aware of the actual protection level they are achieving with sunscreen. Other aspects of the SunSmart message (eg, sun avoidance, wearing protective clothing) should also be reinforced.

Worldwide, skin cancer kills about 50 000 people each year, 80% of the deaths being due to melanoma and most of the rest being due to squamous cell carcinoma. The mortality, morbidity and economic cost of skin damage induced by ultraviolet (UV) radiation is of major relevance to us all. Throughout the world the use of sunscreens is widely promoted, both educationally and commercially, as an important part of the strategy to reduce such skin damage. But are consumers getting what they expect?

It is now reasonably well understood within the medical and scientific community that the level of sun protection factor (SPF) stated on sunscreen products is usually not achieved by users, mainly because the products are applied inadequately.1 Most people apply only enough to achieve an SPF of about a third or even a quarter of the level claimed.2

While the global sunscreen industry and its regulatory bodies (eg, the Therapeutic Goods Administration in Australia and the Food and Drug Administration in the United States) continue to deliberate on the laboratory performance of sunscreens (such as their ability to screen against UVA), there has been less emphasis on how best to encourage adequate (dose-effective) application of sunscreen products. This is despite the recent publication of dosage guides, based on the existing testing procedure, which are designed to ensure that users achieve the level of SPF claimed for products.3,4

Logic would suggest that more effective use of sunscreens would be beneficial, but it is far from clear whether this is the case. There is some evidence that sunscreens used regularly during unintentional sun exposure can prevent squamous cell carcinoma,5 and they appear to reduce the development of solar elastosis. For basal cell carcinoma and melanoma the position is less clear, but recent concerns linking sunscreen use with the development of melanoma appear, so far, to be unfounded.6,7

Yet it is difficult to draw any evidence-based conclusions about sunscreens and their impact on skin cancer, given the known inadequacy and inconsistency of their application. It is not unlike studying the effects of a medication with no consistent dosage specified across subjects.

Application of sunscreen

The internationally accepted sunscreen testing protocol requires that a sunscreen product be applied to a test subject’s skin at an application rate of 2 mg/cm2. It is from this testing process that the SPF of the product is determined. The manufacturer or marketer then uses this figure on the product label to promote its efficacy. (An amount of 2 mg/cm2 equates to approximately two finger lengths of product — about 3 g for an adult — applied to each of 11 areas of the body, each representing about 9% of body surface area [the “rule of nines”].3)

However, for both cosmetic as well as economic reasons, sunscreen users are unlikely to be willing to apply sunscreen at the rate of 2 mg/cm2. It is more likely that, despite such recommendations, they will continue to apply an amount with which they feel comfortable.

So it is surely important for people to be aware of how much protection they are actually achieving — or how much less protection they are achieving than expected.

Options for promoting more effective use of sunscreens

Although it has been known for many years that sunscreens are being inadequately applied,8 there has, until recently, been little official effort to address the problem.

There have been calls to modify the testing procedure to reflect an application rate more in keeping with the amount of product used by consumers (using perhaps a half or even a third of the amount currently applied in testing).9 However, this leads to technical difficulties in the testing procedure because of the difficulty of ensuring uniformity of application.

Another, more practical, proposition has been that the testing system be retained as it stands, but that the stated SPF results be scaled back (perhaps by a factor of 3 or even 4) to reflect a more realistic level of achieved SPF (Peter Gies, Senior Research Scientist, Australian Radiation Protection and Nuclear Safety Agency, personal communication).

Another option is to refine the “SunSmart” message.10 Perhaps the campaign slogan could be changed to something like “SunSmart Plus” or “SunSmart and Sunscreen Smart”, accompanied by a message that gives members of the public a more realistic estimate of the level of protection they will actually achieve from using sunscreen. Given that this will be far less than they previously believed, the public will also need to be encouraged to take greater care in terms of sun avoidance, to regularly reapply sunscreen,11 and to follow the other recommendations of the SunSmart message (eg, wearing sunglasses and protective clothing). If, as a result, they begin to apply more than the “average” amount of sunscreen, so much the better in terms of the protection they will achieve.

  • Stephen R D Taylor

  • Sunset Road Family Doctors, Auckland, New Zealand.


Correspondence: 

Competing interests:

The author is proprietor of Dox Products Ltd, manufacturer of a sunscreen spray in New Zealand — an unconventional, non-Standards Approved product.

  • 1. Gies P, Holmes G. The effective use of sunscreens. Cancer Update in Practice Jan 2003. (A publication of the Cancer Society New Zealand.)
  • 2. Stokes RP, Diffey BL. How well are sunscreen users protected? Photodermatol Photoimmunol Photomed 1997; 13: 186-188.
  • 3. Taylor S, Diffey BL. Simple dosage guide for sunscreens will help users [letter]. BMJ 2002; 324: 1526.
  • 4. Schneider, J. The teaspoon rule of applying sunscreen. Arch Dermatol 2002; 138: 838-839.
  • 5. International Agency for Cancer Research Working Group on the Evaluation of Cancer Preventive Agents. Sunscreens. Lyon, France: IARC, 2001. (IARC handbooks on cancer prevention, Vol 5.)
  • 6. Bastuji-Garin S, Diepgen TL. Cutaneous malignant melanoma, sun exposure, and sunscreen use: epidemiological evidence. Br J Dermatol 2002; 146 Suppl 61: 24-30.
  • 7. Huncharek M, Kupelnick B. Use of topical sunscreens and the risk of malignant melanoma: a meta-analysis of 9067 patients from 11 case–control studies. Am J Public Health 2002; 92: 1173-1177.
  • 8. Bech-Thomsen N, Wulf HC. Sunbathers’ application of sunscreen is probably inadequate to obtain the sun protection factor assigned to the preparation. Photodermatol Photoimmunol Photomed 1992-93; 9: 242-244.
  • 9. Diffey BL. Has the sun protection factor had its day? BMJ 2000; 320: 176-177.
  • 10. Cancer Council Victoria. SunSmart. Available at: www.sunsmart.com.au (accessed Oct 2003).
  • 11. Diffey BL. When should sunscreen be reapplied? J Am Acad Dermatol 2001; 45: 882-885.
  • 12. Diffey B. Sunscreen isn’t enough. J Photochem Photobiol B 2001; 64: 105-108.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.